Headache in Children

1. Clinical Overview

Summary

Headache is one of the most common neurological complaints in childhood, affecting up to 75% of children by age 15 years. [1] While parental anxiety frequently centres on the possibility of brain tumours, more than 90% of recurrent headaches in children are primary headache disorders—predominantly migraine and tension-type headache. [2,3] However, the differential diagnosis must always include serious secondary causes, particularly intracranial pathology, as brain tumours represent the second most common malignancy in childhood. [4]

The clinical approach to paediatric headache requires systematic evaluation using validated diagnostic criteria (ICHD-3), vigilant screening for red flag features, and age-appropriate management strategies. Understanding the unique characteristics of childhood headache presentations—including shorter attack duration, bilateral location, and prominent gastrointestinal symptoms—is essential for accurate diagnosis and effective treatment. [5,6]

The HeadSmart campaign in the UK has significantly improved early detection of brain tumours through standardised red flag criteria and clear referral pathways, demonstrating a reduction in diagnostic interval from 14.3 weeks to 6.7 weeks. [7] This evidence-based approach balances the need to identify serious pathology whilst avoiding unnecessary neuroimaging in children with characteristic primary headache patterns.

Key Clinical Distinctions

Primary vs Secondary Headache:

• Primary (90-95%): Migraine, tension-type headache, trigeminal autonomic cephalalgias
• Secondary (5-10%): Intracranial mass, infection, vascular disorders, systemic disease, medication-related

Paediatric-Specific Features: Childhood headaches differ substantially from adult presentations. Migraines in children are typically shorter (2-4 hours vs 4-72 hours), more commonly bilateral (especially frontal/temporal), and associated with prominent gastrointestinal symptoms including nausea, vomiting, and abdominal pain. [8,9] The classic adult pattern of unilateral, pulsatile, temporal pain emerges gradually during adolescence, particularly in females.

Clinical Pearls

The "School Day Headache" Pattern: A child presenting with headaches exclusively on school days (Monday-Friday), particularly in the afternoon, with complete resolution during weekends and school holidays, should prompt investigation for:

1. Dehydration: Inadequate fluid intake due to restrictive toilet policies or limited access to drinking water during class time
2. Refractive Error: Visual strain from uncorrected myopia, hypermetropia, or astigmatism exacerbated by prolonged near work (reading, screens)
3. Psychosocial Stress: Bullying, academic pressure, social anxiety, or learning difficulties This pattern is rarely due to organic pathology and usually resolves with targeted intervention. [10]

Alice in Wonderland Syndrome (AIWS): A striking migraine aura variant seen predominantly in children aged 5-10 years. The child experiences distorted perception of body image or external objects—typically micropsia (objects appearing smaller) or macropsia (objects appearing larger), but may also include pelopsia (objects appearing closer), teleopsia (farther away), or metamorphopsia (distorted shape). Episodes last 5-30 minutes and can be terrifying for the child and family. The phenomenon is benign and typically resolves by adolescence. AIWS is strongly associated with EBV infection and migraine family history. [11,12]

Occipital Headache as Red Flag: While frontal and temporal pain predominates in primary headaches, isolated occipital headache in a child should raise suspicion for posterior fossa pathology including posterior fossa tumours (medulloblastoma, ependymoma, pilocytic astrocytoma), Chiari malformation, or cerebellar disease. This anatomical correlation warrants neuroimaging in most cases. [13]

Migraine-Stroke Link: Children with migraine with aura have a small but significantly elevated risk of arterial ischaemic stroke compared to headache-free peers (hazard ratio 1.74). This association is particularly relevant in females taking combined hormonal contraceptives and should inform counselling during adolescence. [14]

---

2. Epidemiology and Demographics

Prevalence

Headache prevalence increases progressively throughout childhood and adolescence:

• Age 7 years: 37-51% report any headache; 3.2% report migraine [15]
• Age 11 years: 57-69% report any headache; 5-8% report migraine [15]
• Age 15 years: 70-75% report any headache; 8-23% report migraine [1,15]

Migraine Prevalence by Age and Sex:

• Prepubertal (age less than 12): 6-10% overall; male:female ratio approximately 1:1
• Adolescent (age 12-18): 12-28%; female:male ratio 2-3:1 [16,17]
• Peak incidence: 10-11 years in boys, 14-17 years in girls

Tension-Type Headache:

• Prevalence: 10-25% in school-aged children
• Episodic form more common than chronic
• Equal sex distribution before puberty; slight female predominance after puberty [18,19]

Risk Factors

Genetic Factors:

• Family history present in 70-90% of children with migraine [20]
• First-degree relative with migraine increases risk 2-3 fold
• Specific genetic mutations identified in familial hemiplegic migraine (CACNA1A, ATP1A2, SCN1A genes)

Demographic and Lifestyle Factors:

• Female sex (post-pubertal)
• Low socioeconomic status
• Obesity (OR 1.4-1.6 for chronic daily headache) [21]
• Poor sleep quality and insufficient sleep duration
• High screen time (> 2 hours daily)
• Low physical activity levels
• Dietary irregularity (meal skipping)

Comorbid Conditions:

• Anxiety and depression (OR 2.5-4.8)
• Attention-deficit/hyperactivity disorder (OR 1.7-3.4) [22]
• Epilepsy
• Sleep disorders (sleep apnoea, restless legs syndrome)
• Psychiatric disorders

Impact and Healthcare Burden

• School absence: Children with migraine miss average 4-7 school days per year [23]
• Healthcare utilisation: 1-3% of paediatric emergency department visits
• Quality of life: Significant impairment in physical, emotional, and social functioning
• Economic burden: Estimated annual cost £1.2-2.4 billion (UK) including indirect costs

---

3. Pathophysiology

Primary Headache Mechanisms

Migraine Pathophysiology:

The contemporary understanding of migraine pathophysiology centres on neurovascular mechanisms involving trigeminovascular system activation and cortical spreading depression. [24,25]

1. Cortical Spreading Depression (CSD):

• Self-propagating wave of neuronal and glial depolarisation spreading across cortex at 2-5 mm/minute
• Followed by prolonged suppression of neuronal activity
• Generates visual aura symptoms (scintillating scotoma, fortification spectra)
• Activates trigeminovascular system through release of inflammatory mediators
• Mediated by alterations in potassium, calcium, and glutamate homeostasis

2. Trigeminovascular Activation:

• Trigeminal nerve fibres innervate meningeal blood vessels and dura
• Activation releases vasoactive neuropeptides: CGRP, substance P, neurokinin A
• CGRP (calcitonin gene-related peptide) is the primary mediator:
  • Causes vasodilation of meningeal vessels
  • Promotes neurogenic inflammation
  • Sensitises peripheral nociceptors
  • Levels elevated during migraine attacks and normalise with treatment
• Central sensitisation of trigeminocervical complex neurons amplifies pain signals

3. Brainstem Dysfunction:

• Dorsal pons (periaqueductal grey matter) dysfunction in pain modulation
• Hypothalamic involvement explains premonitory symptoms (yawning, fatigue, food cravings)
• Altered descending pain modulation pathways

4. Genetic Susceptibility:

• Polygenic inheritance in common migraine (60-70% heritability)
• Monogenic in rare subtypes (familial hemiplegic migraine):
  • CACNA1A (P/Q-type calcium channel)
  • ATP1A2 (Na+/K+ ATPase)
  • SCN1A (sodium channel)
• Genes influence neuronal excitability, ion channel function, neurotransmitter release

Tension-Type Headache Pathophysiology:

The mechanisms underlying tension-type headache remain incompletely understood but likely involve:

• Peripheral mechanisms: Increased pericranial muscle tenderness and myofascial trigger points
• Central sensitisation: Altered pain processing in central nervous system
• Psychological factors: Stress, anxiety, and depression modulate pain perception
• Neurotransmitter dysfunction: Reduced serotonergic and endogenous opioid activity [26,27]

Secondary Headache Mechanisms

Raised Intracranial Pressure:

Intracranial mass lesions (tumours, haematomas) cause headache through multiple mechanisms:

• Mass effect: Direct compression and distortion of pain-sensitive structures (dura, blood vessels, cranial nerves)
• Hydrocephalus: Obstruction of CSF pathways with ventricular dilation
• Traction on dura and vessels: Particularly affects meningeal arteries and venous sinuses
• Positional variation: Worsening when supine (reduced venous drainage, increased ICP) explains characteristic early morning headache pattern
• Papilloedema: Optic disc swelling from elevated ICP transmitted along optic nerve sheath

Infection:

• Meningitis: Inflammatory mediators (cytokines, prostaglandins) sensitise meningeal nociceptors
• Sinusitis: Mucosal inflammation and pressure changes in paranasal sinuses
• Systemic infection: Fever-induced vasodilation, cytokine-mediated inflammation

---

4. Clinical Presentation and Classification

ICHD-3 Diagnostic Criteria

The International Classification of Headache Disorders, 3rd edition (ICHD-3) provides standardised diagnostic criteria essential for clinical practice and research. [28]

Migraine Without Aura (Paediatric Criteria)

Diagnostic Criteria:

A. At least 5 attacks fulfilling criteria B-D

B. Headache attacks lasting 2-72 hours (untreated or unsuccessfully treated)

• Note: In children less than 18 years, attacks may last 1-72 hours (shorter than adult criteria)

C. Headache has at least TWO of the following characteristics:

• Bilateral or unilateral location (in children less than 18 years; bilateral location more common, especially frontal/temporal)
• Pulsating quality
• Moderate to severe pain intensity (inhibits or prohibits daily activities)
• Aggravation by or causing avoidance of routine physical activity (e.g., walking, climbing stairs)

D. During headache, at least ONE of the following:

• Nausea and/or vomiting
• Photophobia AND phonophobia (may be inferred from child's behaviour)

E. Not better accounted for by another ICHD-3 diagnosis

Key Paediatric Modifications:

• Shorter minimum duration (2 hours vs 4 hours in adults)
• Bilateral location accepted (whereas adults typically unilateral)
• Photophobia/phonophobia may be behavioural (seeking quiet, dark room)

Migraine With Aura (Paediatric)

Diagnostic Criteria:

A. At least 2 attacks fulfilling criteria B and C

B. One or more of the following fully reversible aura symptoms:

• Visual (most common: scintillating scotoma, fortification spectra, zigzag lines)
• Sensory (paraesthesias, numbness)
• Speech and/or language (dysphasia)
• Motor (weakness—hemiplegic migraine)
• Brainstem (diplopia, dysarthria, vertigo, ataxia, decreased consciousness)
• Retinal (monocular visual disturbance)

C. At least THREE of the following six characteristics:

• At least one aura symptom spreads gradually over ≥5 minutes
• Two or more aura symptoms occur in succession
• Each individual aura symptom lasts 5-60 minutes
• At least one aura symptom is unilateral
• At least one aura symptom is positive (scintillations, tingling)
• Aura accompanied or followed within 60 minutes by headache

D. Not better accounted for by another ICHD-3 diagnosis

Special Paediatric Aura Variants:

• Alice in Wonderland Syndrome: Micropsia, macropsia, metamorphopsia [11]
• Confusional migraine: Acute confusion, agitation, combativeness (posterior circulation variant)
• Hemiplegic migraine: Motor weakness lasting less than 72 hours (familial or sporadic forms)

Tension-Type Headache

Episodic Tension-Type Headache:

A. At least 10 episodes fulfilling criteria B-D

B. Headache lasting 30 minutes to 7 days

C. Headache has at least TWO of the following characteristics:

• Bilateral location
• Pressing/tightening (non-pulsating) quality
• Mild to moderate intensity
• Not aggravated by routine physical activity (climbing stairs, walking)

D. BOTH of the following:

• No nausea or vomiting
• No more than one of photophobia or phonophobia

E. Not better accounted for by another ICHD-3 diagnosis

Clinical Features in Children:

• "Band-like" or "vice-like" sensation around head
• Gradual onset and resolution
• Minimal functional impairment (child can continue activities)
• Often associated with stress, poor posture, eye strain
• May respond to simple analgesia or resolve spontaneously

Chronic Daily Headache

Defined as headache occurring ≥15 days per month for > 3 months. Categories include:

• Chronic migraine
• Chronic tension-type headache
• New daily persistent headache
• Hemicrania continua

Medication Overuse Headache (MOH)

Increasingly recognised in paediatric population (1-2% prevalence). [29]

Diagnostic Criteria:

• Headache ≥15 days per month
• Regular overuse of acute headache medication for > 3 months:
  • "Simple analgesics (paracetamol, ibuprofen): ≥15 days/month"
  • "Triptans, combination analgesics: ≥10 days/month"
• Headache develops or worsens during medication overuse

Clinical Features:

• Progressive increase in headache frequency
• Decreased efficacy of acute medications
• Morning headache
• Anxiety about missing medication doses

Secondary Headache Warning Features

"SNOOP4" Mnemonic for Red Flags:

• Systemic symptoms (fever, weight loss) or Secondary risk factors (immunosuppression, malignancy, pregnancy)
• Neurological signs or symptoms (focal deficits, seizures, altered consciousness, papilloedema)
• Onset sudden, abrupt, thunderclap (subarachnoid haemorrhage, vascular dissection)
• Older age at onset (> 50 years—less applicable in paediatrics, but less than 4 years is concerning)
• Pattern change or recent onset of new headache
• Positional (worse when lying down—raised ICP; worse when upright—low CSF pressure)
• Precipitated by Valsalva, cough, exertion (Chiari malformation, mass lesion)
• Papilloedema or Progressive symptoms (worsening over time)

Specific Paediatric Red Flags:

• Age less than 4 years with severe headache
• Early morning headache with vomiting
• Headache waking child from sleep
• Occipital location
• Abnormal neurological examination
• Personality change or behavioural regression
• Developmental regression or loss of milestones
• New-onset seizures
• Accelerating head circumference (hydrocephalus)

---

5. Clinical Examination

Structured Paediatric Headache Examination

A systematic neurological examination is mandatory in all children presenting with headache to identify features suggesting secondary causes, particularly intracranial pathology.

General Observation

Before Formal Examination:

• Appearance: Unwell, in pain, or comfortable at rest?
• Behaviour: Photophobic (avoiding light), phonophobic (sensitive to noise)?
• Activity level: Playing normally vs withdrawn and lethargic?

Growth Parameters

Essential Measurements:

• Height and weight: Plot on centile charts
  • Growth failure may indicate hypothalamic-pituitary axis pathology (craniopharyngioma)
• Head circumference: Plot on centile charts
  • Accelerating head circumference suggests hydrocephalus
  • Measure if less than 3 years or any concerns
• Blood pressure: Check in all children with headache
  • Hypertensive encephalopathy can present with headache, seizures, visual disturbances
  • Normal values age-dependent (use centile charts)

Cranial Nerve Examination

CN I (Olfactory):

• Rarely tested routinely but anosmia may occur with anterior cranial fossa lesions

CN II (Optic):

• Visual acuity: Snellen chart or age-appropriate test
  • Reduced acuity may indicate optic pathway glioma, raised ICP
• Visual fields: Confrontation testing
  • Bitemporal hemianopia suggests chiasmal lesion (craniopharyngioma, pituitary tumour)
• Fundoscopy: Critical component
  • Papilloedema indicates raised ICP (blurred disc margins, loss of spontaneous venous pulsation, disc elevation, flame haemorrhages)
  • Optic atrophy suggests chronic raised ICP or optic pathway lesion

CN III, IV, VI (Oculomotor, Trochlear, Abducens):

• Eye movements: H-pattern tracking
  • CN VI palsy (failure of abduction) is a false localising sign of raised ICP
  • Diplopia suggests brainstem pathology or raised ICP
• Pupil reactions: Direct and consensual light reflex
  • Asymmetry suggests CN III palsy, Horner syndrome, or structural lesion
• Ptosis: CN III palsy (complete ptosis) vs Horner syndrome (partial ptosis with miosis)

CN V (Trigeminal):

• Facial sensation in three divisions (ophthalmic, maxillary, mandibular)
• Corneal reflex (afferent CN V, efferent CN VII)
• Jaw deviation (muscles of mastication)

CN VII (Facial):

• Facial symmetry at rest and with movement
• Eye closure, smile, puffing cheeks
• Upper motor neuron lesion spares forehead; lower motor neuron affects entire half of face

CN VIII (Vestibulocochlear):

• Gross hearing: Whisper test, finger rub
• Rinne and Weber tests if indicated
• Nystagmus assessment (may indicate cerebellar or brainstem pathology)

CN IX, X (Glossopharyngeal, Vagus):

• Palatal movement: "Say 'aah'"
• Gag reflex (rarely tested unless specific indication)

CN XI (Accessory):

• Shoulder shrug (trapezius)
• Head turn against resistance (sternocleidomastoid)

CN XII (Hypoglossal):

• Tongue protrusion and lateral movement
• Fasciculations, atrophy

Cerebellar Function

Critical for Posterior Fossa Pathology Detection:

D-A-N-I-S-H Approach:

• Dysdiadochokinesia: Rapid alternating movements (pronation-supination)
• Ataxia: Gait assessment (see below)
• Nystagmus: Observe eye movements
• Intention tremor: Finger-nose test, observe for tremor worsening near target
• Speech: Scanning/staccato dysarthria
• Hypotonia: Reduced tone, pendular reflexes

Specific Tests:

• Finger-nose test: Child touches examiner's finger then own nose repeatedly; observe for dysmetria (past-pointing), intention tremor
• Heel-shin test: Run heel down opposite shin; observe for ataxia
• Rapid alternating movements: Pronation-supination of hands; observe for dysdiadochokinesia

Gait Assessment

"Most Important Test" for Posterior Fossa Tumours:

• Normal walking: Observe base width, arm swing, symmetry
• Tandem gait (heel-toe walking): Tests cerebellar midline function
  • Medulloblastoma (vermis) causes broad-based ataxic gait with inability to tandem walk
• On heels: Tests foot dorsiflexion (L4/L5)
• On toes: Tests foot plantarflexion (S1)
• Romberg test: Stand with feet together, eyes closed
  • Positive (falling) indicates posterior column or vestibular dysfunction

Motor Examination

Inspection:

• Muscle bulk, symmetry
• Fasciculations (lower motor neuron signs)
• Abnormal posturing (decorticate, decerebrate)

Tone:

• Assess by passive movement of limbs
• Increased: Upper motor neuron lesion, extrapyramidal disease
• Decreased: Lower motor neuron lesion, cerebellar disease, acute shock

Power:

• MRC grading 0-5
• Test symmetrically in all major muscle groups
• Look for pattern: Hemiparesis (stroke, hemiplegic migraine), paraparesis (spinal cord)

Reflexes:

• Tendon reflexes: Biceps, triceps, supinator, knee, ankle
• Plantar response: Extensor (Babinski sign) abnormal after age 2 years, indicates upper motor neuron lesion
• Clonus: Sustained rhythmic contractions; pathological if > 3 beats

Coordination:

• See cerebellar examination above

Sensory Examination

Light touch, pinprick, temperature, proprioception, vibration:

• Often difficult in younger children
• Look for clear asymmetries or sensory level (spinal cord pathology)

Meningism Assessment

If febrile or acute severe headache:

• Neck stiffness: Passive neck flexion; resistance suggests meningeal irritation
• Kernig sign: Flex hip to 90°, attempt to extend knee; hamstring spasm indicates meningism
• Brudzinski sign: Passive neck flexion causes involuntary hip/knee flexion
• Presence of meningism mandates urgent investigation for meningitis

Skin Examination

Neurocutaneous Syndromes:

• Neurofibromatosis: Café-au-lait macules, axillary freckling (optic pathway glioma risk)
• Tuberous sclerosis: Ash-leaf macules, shagreen patches, facial angiofibromas
• Sturge-Weber syndrome: Facial port-wine stain

---

6. Differential Diagnosis

Primary Headache Disorders (90%)

Secondary Headache Disorders (10%)

Intracranial Pathology

Infection

Vascular

Systemic

---

7. Investigations

Clinical Assessment First

The vast majority of children with headache do NOT require neuroimaging. The decision to investigate depends entirely on clinical assessment identifying red flag features or atypical presentations. [30]

When NOT to Image

Reassuring Primary Headache Pattern:

• Recurrent stereotyped headaches meeting ICHD-3 criteria for migraine or tension-type headache
• Normal neurological examination including fundoscopy
• No red flag features
• Stable pattern over time
• Family history of migraine

NICE Guidance CG150: "Do not perform neuroimaging in children with headaches that are consistent with primary headache disorder and with a normal neurological examination."

When TO Image: HeadSmart Criteria

The HeadSmart: Be Brain Tumour Aware campaign established validated referral criteria for urgent neuroimaging (MRI brain). [7,31]

Persistent Headache Plus One or More:

1. Abnormal neurological examination

   • Cranial nerve abnormality
   • Motor or sensory signs
   • Coordination or gait abnormality
   • Abnormal eye movements or visual fields
   • Papilloedema

2. Behaviour and/or educational performance change

   • Personality change
   • Deteriorating school performance
   • Social withdrawal
   • Developmental regression or loss of milestones

3. Unexplained vomiting

   • Particularly if early morning
   • Not associated with abdominal symptoms
   • Projectile vomiting

4. Seizures

   • New-onset seizures with headache

5. Growth and/or endocrine disorders

   • Growth failure
   • Delayed or precocious puberty
   • Polyuria/polydipsia (diabetes insipidus)
   • Accelerating or decelerating head circumference

6. Headache Features:

   • Headache waking child from sleep
   • Early morning headache
   • Occipital location
   • Worsening over time (progressive pattern)
   • Age less than 4 years

7. Positional or exertional headache

   • Worse with lying down
   • Precipitated by Valsalva, cough, exertion

Urgent Referral Pathway:

• Direct referral to paediatric neurology/oncology
• MRI brain with and without gadolinium contrast
• Target: Scan within 4 weeks for suspected brain tumour
• Emergency referral if acute neurological deterioration

Imaging Modality Selection

MRI Brain (Gold Standard):

• Indications: All red flag headaches, suspected structural pathology
• Advantages: Superior soft tissue resolution, no ionising radiation, multiplanar imaging
• Sequences: T1, T2, FLAIR, diffusion-weighted imaging (DWI), T1 +/- gadolinium
• Sedation: May be required in children less than 6 years (involves anaesthetic risk)
• Specific protocols:
  • Posterior fossa views for cerebellar tumours
  • MR venography (MRV) if venous sinus thrombosis suspected
  • MR angiography (MRA) if vascular malformation suspected

CT Head:

• Limited role in headache evaluation due to radiation exposure
• Emergency indications only:
  • Acute thunderclap headache (subarachnoid haemorrhage detection)
  • Acute head trauma with neurological deterioration
  • Acute hydrocephalus requiring urgent shunt

Primary Care Investigations

Headache Diary:

• The single most valuable diagnostic tool [32]
• Duration: Minimum 4 weeks
• Record: Date, time, duration, location, character, severity (0-10 scale), associated symptoms, triggers, medications taken, activities missed
• Identifies: Patterns, frequency, triggers, medication overuse, temporal relationships

Vision Testing:

• Visual acuity assessment
• Referral to optometrist for formal refraction
• Refractive errors (myopia, hypermetropia, astigmatism) contribute to headache in 5-10% of children

Basic Blood Tests (If Systemically Unwell):

• Full blood count (anaemia, infection, leukaemia)
• Inflammatory markers (CRP, ESR) if infection or vasculitis suspected
• Electrolytes, glucose
• Consider: Thyroid function tests, coeliac screen (if growth concerns)

Specialist Investigations

Lumbar Puncture: Indications:

• Suspected meningitis/encephalitis (fever, neck stiffness)
• Suspected idiopathic intracranial hypertension (measure opening pressure)
• Suspected subarachnoid haemorrhage if CT negative

Contraindications (Relative/Absolute):

• Raised ICP with mass effect (risk of herniation—requires imaging first)
• Coagulopathy or thrombocytopenia
• Local skin infection at puncture site

CSF Analysis:

• Opening pressure (> 25 cm H₂O abnormal; > 28 cm H₂O diagnostic for IIH if no other cause)
• Cell count and differential
• Protein, glucose (with paired serum glucose)
• Microscopy, culture, sensitivity
• Consider: PCR (HSV, enterovirus), oligoclonal bands

Electroencephalography (EEG):

• Limited role in headache evaluation
• Indications: Suspected epilepsy (if loss of consciousness/confusion during episodes), suspected encephalitis
• NOT indicated for routine headache diagnosis

Sleep Study (Polysomnography):

• If symptoms suggest obstructive sleep apnoea (snoring, morning headache, daytime somnolence)

---

8. Management

Management Principles

Paediatric headache management encompasses acute treatment of individual attacks, preventive therapy for frequent disabling headaches, and comprehensive lifestyle modification addressing triggers and perpetuating factors. The approach must be family-centred, developmentally appropriate, and evidence-based. [33,34]

Management Algorithm

                    CHILD WITH HEADACHE
                           ↓
           ┌───────────────┴───────────────┐
           ↓                               ↓
    RED FLAGS PRESENT?            NO RED FLAGS
    ABNORMAL EXAMINATION?         NORMAL EXAMINATION
           ↓                               ↓
    URGENT REFERRAL               PRIMARY HEADACHE
    MRI BRAIN                     LIKELY DIAGNOSIS
    (HeadSmart pathway)                   ↓
                              HEADACHE DIARY × 4 WEEKS
                                          ↓
                     ┌────────────────────┼────────────────────┐
                     ↓                    ↓                    ↓
                 MIGRAINE            TENSION-TYPE         MEDICATION
                                     HEADACHE             OVERUSE
                     ↓                    ↓                    ↓
           ACUTE TREATMENT          LIFESTYLE           WITHDRAW
           + LIFESTYLE              MODIFICATION         ANALGESIA
                     ↓                                   GRADUALLY
           FREQUENT/DISABLING?                          (2-week wean)
           (> 1 attack/week or                                ↓
            > 4 days missed/month)                    HEADACHE DIARY
                     ↓                                MONITOR RESPONSE
                    YES
                     ↓
           PREVENTIVE THERAPY
           (See algorithms below)

Acute Migraine Treatment

Treatment Principles:

1. Early intervention: Medication most effective if taken at headache onset (within 30 minutes)
2. Adequate dosing: Weight-based dosing; underdosing leads to treatment failure
3. Route selection: Oral preferred; alternative routes if vomiting
4. Environmental measures: Dark, quiet room; sleep facilitates recovery

Step 1: Simple Analgesia

Timing: At onset of headache (not waiting for severity to increase) Frequency limit: less than 2-3 days per week to avoid medication overuse headache

Step 2: Triptans (If inadequate response to simple analgesia)

Evidence: Sumatriptan nasal spray demonstrates efficacy in adolescents with 2-hour pain freedom in 65% vs 48% placebo. [37] Oral formulations less consistently effective in trials but real-world effectiveness observed.

Contraindications:

• Hemiplegic migraine or migraine with brainstem aura
• Cardiovascular disease, uncontrolled hypertension
• Concurrent use of ergots or MAOIs

Side effects: Tingling, flushing, tightness (throat/chest—usually benign), dizziness, bad taste (nasal spray)

Step 3: Anti-emetics (For nausea/vomiting)

Gastric stasis: Migraine causes delayed gastric emptying; domperidone/metoclopramide improve absorption of oral analgesia

Non-Pharmacological Acute Measures

Highly Effective in Children:

• Sleep: Often most effective acute treatment; dark, quiet room
• Cold compress: Applied to forehead or temples
• Hydration: Oral rehydration if able; IV fluids if vomiting
• Trigger avoidance: Remove from loud/bright environment

Preventive (Prophylactic) Treatment

Indications for Prevention:

• ≥4 headache days per month with disability
• ≥1 severe attack per week
• Frequent school absence (≥2 days per month)
• Inadequate response to acute treatment
• Patient/family preference
• Contraindication to acute treatments

Important Context: CHAMPS Trial

The landmark CHAMPS trial (Childhood and Adolescent Migraine Prevention Study, NEJM 2017) demonstrated that amitriptyline and topiramate were no more effective than placebo for migraine prevention in children and adolescents aged 8-17 years. [38] This has shifted practice towards:

1. Lifestyle modification as first-line
2. Nutraceuticals (riboflavin, magnesium, CoQ10)
3. Behavioural therapies
4. Reserving pharmacological prophylaxis for refractory cases

Lifestyle and Behavioural Interventions (FIRST-LINE)

Sleep Hygiene:

• Consistent sleep schedule (even weekends)
• 9-11 hours per night (age-dependent)
• Screen-free hour before bedtime
• Cool, dark, quiet bedroom environment

Hydration:

• 1-2 litres water per day (age/weight-dependent)
• Avoid prolonged fasting
• Encourage water bottles at school

Regular Meals:

• Avoid skipping meals (especially breakfast)
• Balanced diet with regular meal times

Physical Activity:

• Regular moderate exercise (30-60 min most days)
• May reduce migraine frequency [39]

Stress Management:

• Cognitive behavioural therapy (CBT)
• Relaxation techniques (progressive muscle relaxation, guided imagery)
• Biofeedback
• Mindfulness

Trigger Identification and Avoidance:

• Use headache diary to identify personal triggers
• Common triggers: Sleep deprivation, dehydration, stress, specific foods (chocolate, cheese, caffeine), weather changes, bright lights

Nutraceuticals (SECOND-LINE)

Evidence-Based Supplements:

Combination approach: Some clinicians use riboflavin + magnesium + CoQ10 combination ("Triple Therapy")

Safety: Excellent safety profiles; minimal side effects; placebo-like tolerability

Pharmacological Prophylaxis (THIRD-LINE)

Prescribe only if lifestyle/nutraceuticals ineffective and headache disability significant.

First-Line Pharmacological Options:

Second-Line Options (Specialist Use):

Duration of Prophylaxis:

• Trial for 3-6 months minimum
• If effective (≥50% reduction in headache frequency), continue 6-12 months total
• Gradual withdrawal to assess ongoing need
• Reassess at 6 months: Many children experience improvement with time

Emerging Therapies:

• CGRP monoclonal antibodies (erenumab, fremanezumab): Licensed for adults; paediatric trials ongoing
• OnabotulinumtoxinA (Botox): Licensed for chronic migraine in adults; limited paediatric data

Tension-Type Headache Management

Acute Treatment:

• Simple analgesia: Paracetamol or ibuprofen
• Usually milder, responds quickly
• Avoid frequent use (risk of MOH)

Preventive Strategies (PRIMARY FOCUS):

• Lifestyle modification: Sleep, hydration, regular meals
• Stress reduction: CBT, relaxation techniques
• Ergonomic assessment: School desk setup, posture
• Vision correction: Refractive error treatment
• Physical therapy: If myofascial component (neck/shoulder tension)
• Psychological support: If anxiety/depression underlying

Pharmacological prophylaxis rarely indicated for tension-type headache

Medication Overuse Headache Management

Withdrawal Strategy:

1. Education: Explain mechanism and need for withdrawal
2. Gradual taper over 2-4 weeks (abrupt cessation may cause withdrawal headache)
3. Bridge therapy: Consider short course of different acute medication (triptan if was using simple analgesia; alternative NSAID)
4. Preventive therapy: Start prophylaxis concurrently
5. Behavioural support: CBT, headache diary monitoring
6. Follow-up: Close monitoring during withdrawal period

Expected course: Headache often worsens initially (days 2-10) before improvement (weeks 2-4)

Prognosis: 50-70% improvement in headache frequency after successful withdrawal [42]

Status Migrainosus Management

Definition: Migraine attack lasting > 72 hours

Hospital Management:

• IV fluids: Rehydration (isotonic saline or dextrose/saline)
• IV antiemetics: Ondansetron, metoclopramide
• IV NSAIDs: Ketorolac 0.5 mg/kg (max 30 mg)
• IV corticosteroids: Dexamethasone 0.15-0.6 mg/kg (max 12 mg) may break cycle [43]
• IV dihydroergotamine: Specialist use; contraindicated if triptans used within 24 hours
• Chlorpromazine: 0.1-0.2 mg/kg IV; effective but risk of dystonia, hypotension

Multidisciplinary Management

Paediatric Headache Service Components:

• Paediatric neurologist
• Paediatric psychologist (CBT, biofeedback)
• Specialist headache nurse
• Physiotherapist (if myofascial/cervicogenic component)
• Dietitian (if dietary triggers identified)
• Safeguarding team (if significant school absence/illness behaviour concerns)

When to Refer to Specialist

Indications for Paediatric Neurology Referral:

• Red flag features (see Section 7)
• Diagnosis uncertain
• Refractory to primary care management
• Frequent school absence (> 2 days/month)
• Hemiplegic migraine or other complicated migraine
• Age less than 5 years with recurrent headache
• Significant impact on quality of life/function
• Medication overuse headache

---

9. Complications and Associated Conditions

Migraine Complications

Status Migrainosus:

• Migraine attack lasting > 72 hours
• Significant disability, dehydration risk
• May require hospitalisation (IV fluids, IV medications)

Migrainous Infarction:

• Ischaemic stroke occurring during migraine with aura
• Aura symptoms persist > 60 minutes; imaging confirms infarction
• Rare but recognised complication, particularly in posterior circulation
• Risk factors: Female, oral contraceptive use, prolonged aura

Persistent Aura Without Infarction:

• Aura symptoms lasting > 1 week without imaging evidence of infarction
• Requires investigation to exclude stroke
• Usually self-limiting but may require preventive therapy

Migraine-Triggered Seizure (Migralepsy):

• Seizure occurring during or within 1 hour of migraine aura
• Rare phenomenon
• Diagnostic criteria contentious; overlap between migraine and epilepsy

Psychosocial Complications

School Absence and Educational Impact:

• Children with migraine miss average 4-7 school days per year [23]
• Chronic daily headache can lead to prolonged school absence
• Risk of falling behind academically
• Social isolation from missed peer interactions

Illness Behaviour and School Refusal:

• Headache becomes mechanism for avoiding school
• Secondary gain (attention, avoiding stressors)
• Requires psychological assessment and behavioural intervention
• Distinguish from malingering (child genuinely experiences pain)

Anxiety and Depression:

• Bidirectional relationship: Headache increases anxiety/depression risk; psychiatric disorders worsen headache
• Prevalence of anxiety disorders 2-4× higher in children with migraine [44]
• Screening tools: RCADS (Revised Child Anxiety and Depression Scale), SDQ (Strengths and Difficulties Questionnaire)

Quality of Life Impairment:

• Physical functioning: Reduced ability to exercise, play sports
• Social functioning: Missed social events, parties, activities
• Emotional functioning: Worry about next attack, sense of unpredictability
• School functioning: Concentration difficulties, academic performance

Comorbid Medical Conditions

Epilepsy:

• Migraine and epilepsy co-occur more frequently than expected by chance
• Shared pathophysiological mechanisms (cortical hyperexcitability, ion channel dysfunction)
• Valproate effective for both conditions

Sleep Disorders:

• Obstructive sleep apnoea: Morning headache, witnessed apnoeas, snoring
• Restless legs syndrome
• Insomnia and insufficient sleep exacerbate migraine

Obesity:

• Obese children have 1.4-1.6× increased risk of chronic daily headache [21]
• Proposed mechanisms: Systemic inflammation, sleep apnoea, medication adherence

Attention-Deficit/Hyperactivity Disorder (ADHD):

• ADHD prevalence 2-3× higher in children with migraine [22]
• Shared genetic susceptibility
• Dopaminergic system dysfunction common to both

Diagnostic Pitfalls (Missed or Delayed Diagnosis)

Brain Tumour:

• Average diagnostic delay historically 14 weeks before HeadSmart campaign [7]
• Symptoms often attributed to primary headache, viral illness, psychological factors
• Posterior fossa tumours (medulloblastoma, ependymoma, pilocytic astrocytoma) most common
• HeadSmart reduced delay to 6.7 weeks through awareness campaign

Idiopathic Intracranial Hypertension (IIH):

• Obesity, female adolescent, presents with headache and visual symptoms
• Papilloedema may be subtle initially
• Risk of permanent visual loss if untreated
• Requires lumbar puncture for diagnosis (opening pressure > 25 cm H₂O)

Chiari Malformation:

• Cerebellar tonsils herniate through foramen magnum
• Classic presentation: Occipital headache worsened by cough, Valsalva, exertion
• May have associated syrinx (syringomyelia) causing dissociated sensory loss
• MRI diagnostic

Cervical Artery Dissection:

• Neck pain/headache followed by stroke symptoms
• History of minor trauma (contact sports, chiropractic manipulation) or spontaneous
• Horner syndrome (ptosis, miosis, anhidrosis) ipsilateral to dissection
• MRA/CTA diagnostic

---

10. Prognosis and Long-Term Outcomes

Natural History of Childhood Migraine

Remission Rates:

• Approximately 50% of children with migraine experience remission or marked improvement during adolescence [45]
• Boys more likely to remit (60-70%) than girls (30-40%)
• Girls often transition to menstrual-related migraine patterns

Persistence into Adulthood:

• 30-50% continue to experience migraine in adulthood
• Female predominance increases post-puberty (3:1 female:male ratio)
• Chronic migraine (≥15 days/month) develops in 3-5%

Factors Predicting Persistence:

• Female sex
• Early age of onset (less than 7 years)
• Positive family history (both parents affected)
• High attack frequency at baseline
• Comorbid psychiatric disorders
• Medication overuse

Functional Outcomes

Academic Performance:

• Migraine associated with reduced school attendance, concentration difficulties
• With effective treatment, most children maintain normal academic trajectory
• Chronic daily headache associated with greater academic impairment

Quality of Life:

• Effective headache management improves health-related quality of life across all domains [46]
• Psychological interventions (CBT) provide sustained benefit beyond headache frequency reduction

Psychosocial Adjustment:

• Most children with well-managed migraine have normal psychosocial development
• Inadequate treatment associated with increased anxiety, depression, school refusal

Brain Tumour Outcomes

Survival Rates (Highly Variable by Histology):

• Pilocytic astrocytoma: > 90% 5-year survival (often curable with complete resection)
• Medulloblastoma: 70-80% 5-year survival (treatment: surgery + chemotherapy + radiotherapy)
• Ependymoma: 60-75% 5-year survival (varies by location and grade)
• Diffuse intrinsic pontine glioma (DIPG): less than 10% 2-year survival (universally poor prognosis)

Impact of Early Diagnosis:

• HeadSmart campaign demonstrated improved survival through earlier diagnosis [7]
• Reduced diagnostic interval correlates with reduced morbidity (visual loss, hydrocephalus complications)

Tension-Type Headache Prognosis

Generally Favourable:

• Episodic tension-type headache often improves with lifestyle modification
• Chronic tension-type headache more persistent but manageable with behavioural interventions
• Rarely causes significant long-term disability if appropriately managed

Medication Overuse Headache Outcomes

With Successful Withdrawal:

• 50-70% experience significant improvement in headache frequency [42]
• Relapse rate 20-30% within first year (requires ongoing monitoring)
• Early intervention improves prognosis

---

11. Evidence and Guidelines

Key Clinical Guidelines

Landmark Evidence

1. CHAMPS Trial (Powers et al., NEJM 2017) [38]

Study Design: Randomised, double-blind, placebo-controlled trial

• Population: 328 children and adolescents (8-17 years) with migraine
• Intervention: Amitriptyline (1 mg/kg, max 100 mg) vs Topiramate (2 mg/kg, max 200 mg) vs Placebo
• Duration: 24 weeks
• Primary Outcome: Reduction in headache days from baseline

Results:

• Placebo: 61.4% achieved ≥50% reduction in headache days
• Amitriptyline: 52.2% achieved ≥50% reduction
• Topiramate: 54.7% achieved ≥50% reduction
• No significant difference between groups (p=0.48)

Implications:

• Neither amitriptyline nor topiramate superior to placebo for migraine prevention in children/adolescents
• High placebo response rate reflects importance of natural history, regression to mean, non-specific effects
• Shifted practice towards lifestyle interventions and nutraceuticals as first-line preventive strategies
• Reinforced importance of placebo-controlled trials in paediatric headache research

2. HeadSmart Campaign (Wilne et al., Arch Dis Child 2012) [7]

Study Design: Before-and-after evaluation of symptom awareness campaign

• Population: Children diagnosed with brain tumours in UK
• Intervention: National awareness campaign targeting parents and healthcare professionals with standardised symptom recognition and referral guidelines

Results:

• Diagnostic interval reduced from 14.3 weeks to 6.7 weeks (median)
• Proportion diagnosed within 4 weeks increased from 25% to 47%
• Earlier detection correlated with reduced morbidity (visual impairment, hydrocephalus requiring emergency shunt)

Implications:

• Standardised red flag criteria improve early diagnosis
• Public and professional education campaigns effective in reducing diagnostic delay
• Provides validated framework for urgent referral decisions in primary care

3. Sumatriptan Nasal Spray in Adolescents (Winner et al., Pediatrics 2000) [37]

Study Design: Randomised, double-blind, placebo-controlled trial

• Population: 302 adolescents (12-17 years) with migraine
• Intervention: Sumatriptan nasal spray (5 mg, 10 mg, 20 mg) vs placebo
• Primary Outcome: Headache relief at 2 hours

Results:

• 20 mg sumatriptan: 65% headache relief vs 48% placebo (pless than 0.05)
• 10 mg sumatriptan: 60% headache relief
• 5 mg sumatriptan: Similar to placebo

Implications:

• Sumatriptan nasal spray 10-20 mg effective for acute migraine in adolescents
• Led to licensing of sumatriptan nasal spray for ages 12-17 years
• Established triptans as safe and effective option for paediatric migraine

4. Riboflavin for Migraine Prevention (Bruijn et al., Neurology 2010) [40]

Study Design: Open-label prospective study

• Population: 42 paediatric patients with migraine
• Intervention: Riboflavin 400 mg daily
• Duration: 3-6 months

Results:

• 68% achieved ≥50% reduction in headache frequency
• Excellent tolerability: No serious adverse events
• Responder rate comparable to pharmacological prophylaxis but superior safety profile

Implications:

• Riboflavin represents safe, well-tolerated preventive option
• Appropriate first-line preventive intervention before pharmacological agents
• Mechanism: Improves mitochondrial energy metabolism

5. Cognitive Behavioural Therapy for Paediatric Migraine (Powers et al., JAMA 2013) [49]

Study Design: Randomised controlled trial

• Population: 135 adolescents (10-17 years) with migraine
• Intervention: CBT + amitriptyline vs headache education + amitriptyline
• Duration: 20 weeks treatment, 12 months follow-up

Results:

• CBT + amitriptyline: 66% achieved ≥50% reduction vs 36% education + amitriptyline (p=0.003)
• Sustained benefit at 12-month follow-up
• Reduced disability and improved quality of life

Implications:

• CBT provides additive benefit to pharmacological treatment
• Behavioural interventions should be integrated into comprehensive headache management
• Effect sizes comparable to or exceeding pharmacological monotherapy

---

12. Patient and Family Education

Addressing Parental Concerns

"Does my child have a brain tumour?"

I completely understand your concern—this is the first question most parents ask, and it's natural to worry about serious causes. I have specifically examined your child for signs of raised pressure in the brain. I have:

• Looked at the back of their eyes (fundoscopy) to check for swelling of the optic nerve, which would indicate pressure on the brain
• Checked their balance and coordination (asking them to walk heel-to-toe)
• Tested their eye movements, strength, and reflexes

All of these examinations are completely normal. Additionally, your child's headaches fit the typical pattern for migraine:

• They come and go (not constantly present or getting progressively worse)
• They have a family history of migraine (you mentioned your sister gets migraines)
• The pain is throbbing and associated with nausea
• They improve with rest and sleep

Brain tumours are very rare, affecting approximately 3 in 100,000 children. When they do occur, they usually cause specific warning signs that we actively look for (and your child doesn't have). The HeadSmart campaign has taught us exactly what to look for, and I can reassure you that your child does not have these features.

"But the headaches are so severe—how can this be normal?"

Migraine is a genuine neurological condition, not "just a headache." During an attack, the brain's pain pathways become hypersensitive, and blood vessels around the brain dilate, causing intense throbbing pain. It's a real, physical process—not psychological or imaginary.

The good news is that migraine is very treatable. With the right approach, we can significantly reduce how often attacks happen and how severe they are when they do occur.

"Why does my child vomit so much?"

Vomiting is actually a cardinal feature of migraine in children—more so than in adults. During a migraine attack, the stomach stops working properly (a process called "gastric stasis"). This is why children often vomit and why giving medication as soon as the headache starts (before vomiting begins) is so important.

There's also a related condition called abdominal migraine where children have episodes of tummy pain, nausea, and vomiting without the headache. Many children with abdominal migraine later develop typical migraine headaches as they get older.

Understanding Migraine: Layperson Explanation

What is migraine?

Migraine is a neurological condition where the brain becomes temporarily oversensitive to normal signals. Think of it like a "storm" in the brain that causes:

• Intense, throbbing headache (usually at the front or sides of the head)
• Feeling sick or being sick
• Sensitivity to light and noise
• Need to lie down in a dark, quiet room

Why does it happen?

Migraine runs in families (genetic). If you or your partner get migraines, your child has a higher chance of experiencing them too. During an attack:

1. Nerve cells in the brain fire in an unusual wave-like pattern
2. This activates pain nerves around blood vessels in the brain
3. These blood vessels dilate (widen) and release inflammatory chemicals
4. The pain signals travel to the brain, causing the headache

What triggers attacks?

Common triggers in children include:

• Lack of sleep or oversleeping
• Dehydration (not drinking enough water)
• Skipping meals (irregular eating)
• Stress (exams, arguments, bullying)
• Bright lights or loud noises
• Weather changes
• Certain foods (chocolate, cheese, caffeine) in some children
• Screens (too much time on phones, tablets, computers)

Will it get better?

Yes! About half of children with migraine find their attacks reduce or stop completely during their teenage years, especially boys. Girls may continue to have migraines but often find they become more manageable.

Treatment Plan (Family-Friendly)

During an Attack (Acute Treatment):

1. Act Fast: Give medication as soon as the headache starts—don't wait for it to get worse

   • Ibuprofen (Nurofen): 10 mg per kilogram (usually 200-400 mg depending on age)
   • At the first sign of headache (within first 30 minutes is ideal)

2. Rest:

   • Dark, quiet room
   • Sleep if possible (often the best medicine)
   • Cool flannel on forehead

3. Hydration:

   • Sips of water (even if feeling sick)
   • If vomiting, try small amounts frequently

4. What NOT to do:

   • Don't give painkillers more than 2-3 days per week (can make headaches worse—"medication overuse headache")

Preventing Future Attacks (Lifestyle First):

1. Sleep Routine:

   • Same bedtime every night (including weekends)
   • 9-11 hours sleep per night (depending on age)
   • No screens 1 hour before bed

2. Water:

   • Drink water throughout the day
   • Take a water bottle to school
   • Target: 6-8 glasses per day (age-dependent)

3. Regular Meals:

   • Never skip breakfast
   • Eat every 3-4 hours during the day

4. Exercise:

   • Regular physical activity (30-60 minutes most days)
   • But avoid exercising when already having a headache

5. Trigger Diary:

   • Keep a headache diary for 4 weeks
   • Record: Date, time, what they ate, how much sleep, stress levels, when headache started
   • This helps identify your child's personal triggers

When to Consider Preventive Medication:

If lifestyle changes don't help enough and your child is:

• Missing school regularly (2+ days per month)
• Having severe attacks more than once per week
• Significantly impacting quality of life (can't do activities, sports, socialise)

Then we can discuss daily preventive medication. These are taken every day (even when no headache) to reduce how often attacks occur.

When to Seek Urgent Medical Attention

Call 999 or go to A&E if:

• Sudden, severe "thunderclap" headache (worst headache ever, came on in seconds)
• Headache with stiff neck and fever (possible meningitis)
• Headache with weakness, numbness, slurred speech, or vision loss
• Headache after significant head injury
• Headache with confusion or altered consciousness
• Severe headache that doesn't respond to usual treatment and is getting worse

See GP urgently (same day/next day) if:

• Headache waking child from sleep
• Early morning headache with vomiting
• Personality change or school performance decline
• Any new neurological symptoms (balance problems, clumsiness, squint)

Returning to School

Managing School Attendance:

Migraine is a legitimate medical condition, but with good management, most children can maintain regular school attendance. Work with the school to:

• Inform teachers about your child's diagnosis
• Arrange for water bottle at desk (hydration)
• Allow child to take medication at school if needed (coordinate with school nurse)
• Provide quiet space for child to rest if headache develops
• Adjust seating (away from bright windows if light-sensitive)
• Consider reduced screen time during lessons if triggers identified
• Arrange catch-up plan if school missed

Avoiding "Illness Behaviour":

It's important to:

• Encourage return to school as soon as headache resolves
• Avoid prolonged absence (can worsen anxiety and create school avoidance pattern)
• Distinguish genuine attacks from school-related stress (headaches only on school days may indicate underlying issue requiring different approach)

---

13. Special Populations and Considerations

Adolescent Females

Menstrual-Related Migraine:

• Migraine attacks occurring perimenstrually (days -2 to +3 of menstruation)
• Prevalence increases post-menarche (affects 20-40% of adolescent females with migraine)
• Mechanism: Estrogen withdrawal triggers attacks
• Management:
  • Acute treatment as per standard migraine protocols
  • "Short-term prophylaxis: NSAIDs (mefenamic acid, naproxen) perimenstrually"
  • Hormonal manipulation rarely needed in adolescents

Contraception Counselling:

• Migraine with aura is contraindication to combined hormonal contraceptives (CHC) due to increased stroke risk (UKMEC 4)
• Migraine without aura is relative contraindication (UKMEC 3) if additional risk factors present
• Progesterone-only methods safe (UKMEC 2)
• Important to ask about aura symptoms before prescribing CHC

Preschool Children (Age less than 5 Years)

Diagnostic Challenges:

• Difficulty articulating headache symptoms (may present as irritability, behavioural change)
• Cannot reliably complete headache diaries
• Differential diagnosis broader (include developmental and metabolic disorders)

Red Flag: Age less than 4 years with severe headache warrants imaging (higher pre-test probability of structural pathology)

Management Considerations:

• Non-pharmacological strategies paramount (sleep, hydration, routine)
• Medication dosing weight-based and requires careful calculation
• Many medications not licensed for very young children (use off-label with caution)

Children with Learning Disabilities

Assessment Challenges:

• May be unable to verbalise headache symptoms
• Behavioural change may be only indicator (irritability, self-injurious behaviour, social withdrawal)
• Pain assessment tools: Observational scales (FLACC, NCCPC-R)

Higher Threshold for Imaging:

• Difficulty assessing neurological examination
• Cannot reliably report red flag symptoms
• Consider lower threshold for MRI if diagnostic uncertainty

Athletes and Active Children

Exertional Headache:

• Benign primary exertional headache (triggered by intense exercise)
• Differential diagnosis: Cardiac causes, vascular malformations (requires investigation on first presentation)

Return to Sport After Head Injury:

• Post-concussion headache common
• Graduated return-to-play protocol (stepwise increase in activity)
• Must be symptom-free before full return to contact sports

Cultural and Linguistic Considerations

Language Barriers:

• Use professional interpreters (not family members) for accurate assessment
• Visual analogue scales and pictorial pain scales helpful
• Translated patient information resources

Cultural Perceptions of Pain:

• Some cultures more expressive of pain symptoms; others stoic
• Beliefs about illness causation (spiritual, dietary, environmental)
• Respect cultural practices while providing evidence-based care

---

14. Examination Focus: MRCPCH and Paediatric Neurology

High-Yield Exam Topics

1. Red Flags and Urgent Referral:

• Question stem: "Which feature would mandate urgent MRI in a child with headache?"
• Key answers: Early morning headache with vomiting, papilloedema, ataxia, age less than 4 years, headache waking from sleep, occipital location, progressive pattern, abnormal neurological examination

2. ICHD-3 Diagnostic Criteria:

• Migraine without aura (paediatric modifications): ≥5 attacks, 2-72 hours duration, bilateral/frontal location accepted, pulsating, moderate-severe, nausea/vomiting or photophobia/phonophobia
• Key distinction from adults: Shorter duration (2h vs 4h), bilateral more common

3. Acute Migraine Treatment:

• First-line: Ibuprofen 10 mg/kg (superior to paracetamol)
• Triptans: Sumatriptan nasal spray licensed age ≥12 years (10-20 mg depending on weight)
• Timing: Early administration critical

4. Migraine Prophylaxis:

• CHAMPS trial: Amitriptyline and topiramate NO better than placebo
• Current practice: Lifestyle first-line, nutraceuticals second-line (riboflavin 400 mg, magnesium), pharmacological third-line (pizotifen, propranolol)
• Pizotifen side effect: Weight gain (teenagers often refuse)

5. Medication Overuse Headache:

• Criteria: ≥15 days/month headache with regular medication overuse > 3 months
• Management: Gradual withdrawal, preventive therapy, behavioural support
• Threshold: ≥15 days/month simple analgesics OR ≥10 days/month triptans

6. Examination Findings:

• Papilloedema: Blurred disc margins, loss of cup, disc elevation, flame haemorrhages (indicates raised ICP)
• CN VI palsy: Failure of abduction (false localising sign of raised ICP)
• Ataxia: Broad-based gait, inability to tandem walk (posterior fossa pathology)

7. Special Migraine Variants:

• Alice in Wonderland Syndrome: Micropsia/macropsia (visual distortion), benign migraine aura variant, ages 5-10 years
• Abdominal migraine: Recurrent episodes of central abdominal pain, nausea, pallor without headache; family history of migraine; evolves into migraine later
• Hemiplegic migraine: Motor weakness during aura (less than 72h); can be familial (CACNA1A, ATP1A2, SCN1A mutations) or sporadic

8. HeadSmart Campaign:

• Purpose: Early identification of childhood brain tumours
• Impact: Reduced diagnostic interval from 14.3 weeks to 6.7 weeks
• Key red flags: See Section 7

Common MRCPCH Clinical Scenarios

Scenario 1: Primary Headache vs Secondary Headache

"An 11-year-old girl presents with 6-month history of episodic frontal headaches occurring 2-3 times per month. They last 3-4 hours, are throbbing in nature, associated with nausea, and she needs to lie down in a dark room. Her mother has migraines. Examination is entirely normal including fundoscopy. What is the most appropriate next step?"

Answer: Headache diary for 4 weeks + acute treatment with ibuprofen. No imaging required (reassuring primary headache pattern; normal examination).

Scenario 2: Brain Tumour Presentation

"A 7-year-old boy presents with 8-week history of progressive headaches, now occurring daily. They are worse in the morning and associated with vomiting. He has become clumsy over the past 2 weeks. On examination, he has an ataxic gait and bilateral papilloedema. What is the diagnosis and immediate management?"

Answer: Posterior fossa tumour (likely medulloblastoma or ependymoma) causing raised ICP. Immediate management: Urgent MRI brain, neurosurgical referral, consider IV dexamethasone to reduce perilesional oedema.

Scenario 3: Migraine Prophylaxis

"A 14-year-old girl with migraine has tried lifestyle modifications (regular sleep, hydration, trigger avoidance) without improvement. She is missing school 4 days per month. What preventive treatment options would you discuss?"

Answer:

• First-line: Nutraceuticals (riboflavin 400 mg daily, magnesium)
• Second-line: Pharmacological prophylaxis (pizotifen 0.5-1.5 mg daily, propranolol 1-2 mg/kg/day BID-TID)
• Counselling: Weight gain risk with pizotifen; propranolol contraindicated in asthma; trial 3-6 months minimum

Scenario 4: Medication Overuse Headache

"A 13-year-old boy with known migraine now has daily headaches. He has been taking ibuprofen 5-6 days per week for the past 4 months. What is the likely diagnosis and management?"

Answer: Medication overuse headache. Management: Education about mechanism, gradual withdrawal of ibuprofen over 2-4 weeks, start preventive therapy (e.g., riboflavin), CBT/behavioural support, close follow-up. Warn that headache may worsen initially before improving.

Viva Voce Preparation

Viva Topic 1: Approach to Childhood Headache

Examiner: "How would you assess a child presenting to clinic with recurrent headaches?"

Structure your answer using SOCRATES + Red Flags:

History:

• Site: Where is the pain? (frontal, temporal, occipital)
• Onset: When did it start? Sudden or gradual? First episode or recurrent?
• Character: What does it feel like? (throbbing, pressing, sharp, dull)
• Radiation: Does it spread anywhere?
• Associated symptoms: Nausea, vomiting, photophobia, phonophobia, aura, focal neurology
• Time course: How long does each episode last? (2-72 hours migraine)
• Exacerbating/relieving: Worse with activity? Better with rest/sleep?
• Severity: Pain scale 0-10; functional impact (missing school, stopping activities)

Red Flags (SNOOP4): See Section 4

Pattern Recognition:

• Frequency, duration, timing (morning/evening/nocturnal)
• Triggers (stress, sleep deprivation, dehydration, foods, screens, menstruation)
• Family history (migraine strongly familial)
• Developmental and educational impact
• Psychosocial factors (bullying, anxiety, school refusal)

Examination:

• Growth parameters (height, weight, head circumference)
• Blood pressure
• Comprehensive neurological examination (cranial nerves, fundoscopy, cerebellar function, gait, motor/sensory, reflexes)

Investigations:

• Headache diary (gold standard diagnostic tool)
• Vision testing (refractive error)
• MRI brain if red flags present
• No investigation if reassuring primary headache pattern

Management:

• Acute treatment (ibuprofen, triptans if appropriate)
• Preventive strategies (lifestyle first-line)
• Education and reassurance
• Multidisciplinary approach (psychology, physiotherapy if indicated)

Viva Topic 2: Migraine Pathophysiology

Examiner: "Can you explain the pathophysiology of migraine?"

Answer Framework:

Migraine is a neurovascular disorder involving complex interactions between the brain, meningeal blood vessels, and trigeminal nervous system. Three key mechanisms:

1. Cortical Spreading Depression (CSD):

• Wave of neuronal depolarisation spreading across cortex at 2-5 mm/min
• Followed by suppression of neuronal activity
• Generates aura symptoms (visual most common—scintillating scotoma)
• Activates trigeminovascular system

2. Trigeminovascular Activation:

• Trigeminal nerve fibres innervate meningeal blood vessels
• Activation releases CGRP (calcitonin gene-related peptide), substance P, neurokinin A
• CGRP causes vasodilation and neurogenic inflammation
• Sensitises peripheral nociceptors (pain receptors)
• Levels elevated during attack and normalise with triptan treatment

3. Central Sensitisation:

• Trigeminocervical complex neurons in brainstem become sensitised
• Amplify pain signals
• Explain allodynia (normal stimuli perceived as painful—e.g., brushing hair hurts)

4. Brainstem and Hypothalamic Dysfunction:

• Dorsal pons (periaqueductal grey) dysfunction in pain modulation
• Hypothalamus involved in premonitory symptoms (yawning, food cravings, mood change)

Genetic Component:

• 60-70% heritability in common migraine (polygenic)
• Monogenic in rare familial hemiplegic migraine (ion channel mutations)

Viva Topic 3: When to Image

Examiner: "When would you request neuroimaging in a child with headache?"

Answer:

Do NOT image if:

• Recurrent headaches meeting ICHD-3 criteria for primary headache (migraine or tension-type)
• Normal neurological examination including fundoscopy
• No red flag features
• Stable pattern over time
• NICE CG150: "Do not perform neuroimaging in children with headaches consistent with primary headache disorder and normal neurological examination"

DO image (MRI brain) if ANY of these HeadSmart red flags:

1. Abnormal neurological examination (papilloedema, ataxia, focal signs, CN palsies)
2. Behaviour or school performance change (personality, developmental regression)
3. Headache waking from sleep or early morning headache
4. Occipital location (rare in primary headache)
5. Age less than 4 years with severe headache
6. Progressive pattern (increasing frequency/severity)
7. Positional or exertional headache
8. Seizures with headache
9. Growth/endocrine problems (failure to thrive, diabetes insipidus)
10. Sudden thunderclap onset (subarachnoid haemorrhage)

Imaging modality: MRI brain (with and without gadolinium contrast) is gold standard. CT only for emergency situations (acute trauma, suspected acute hydrocephalus).

---

15. Clinical Pearls and Pitfalls

Clinical Pearls

1. Migraine is a diagnosis of pattern recognition, not exclusion. Don't over-investigate children with classic migraine and normal examination.

2. Fundoscopy is mandatory in every child with headache. Papilloedema changes practice from reassurance to urgent imaging.

3. "School day headaches" (Mon-Fri, absent weekends/holidays) are rarely organic. Think dehydration, refractive error, or psychosocial stress.

4. Occipital headache is a red flag in children. Frontal/temporal is typical for primary headaches; occipital suggests posterior fossa pathology.

5. The headache diary is the most valuable diagnostic tool—more useful than blood tests or scans in primary headache.

6. Early medication administration is the single most important factor in acute migraine treatment efficacy. "Take it as soon as headache starts" not "wait and see if it gets bad."

7. Lifestyle modification is first-line prophylaxis—more evidence for riboflavin/magnesium than for amitriptyline/topiramate (CHAMPS trial).

8. Pizotifen causes weight gain—adolescents often refuse it; discuss this side effect upfront and consider propranolol as alternative.

9. Alice in Wonderland Syndrome is benign—terrifying for child and parents but completely harmless migraine aura variant.

10. Medication overuse headache is increasingly common in children (1-2%). Ask specifically about analgesic frequency.

Common Pitfalls

1. Falsely reassuring complex migraine for stroke/TIA: Hemiplegic migraine can mimic stroke (weakness lasting less than 72h). Investigate first presentation with imaging +/- genetic testing.

2. Attributing morning vomiting to "gastroenteritis" when it's actually raised ICP from posterior fossa tumour. Morning vomiting + headache = red flag.

3. Treating tension-type headache with prophylactic medication instead of addressing underlying stress/anxiety with CBT.

4. Scanning every child with headache to "reassure parents"—unnecessary radiation/sedation risks; doesn't reduce anxiety long-term; reinforces illness beliefs.

5. Missing idiopathic intracranial hypertension in obese adolescent females—easy to attribute symptoms to primary headache without fundoscopy.

6. Forgetting to check blood pressure—hypertensive encephalopathy presents with headache, seizures, visual disturbances.

7. Overlooking medication overuse headache—if headaches are becoming more frequent despite treatment escalation, ask about analgesic use patterns.

8. Assuming bilateral headache excludes serious pathology—childhood migraines are typically bilateral; bilaterality does NOT rule out secondary causes.

9. Focusing solely on headache when child has multiple symptoms—don't miss meningitis (fever, neck stiffness, photophobia, rash).

10. Inadequate safety-netting—always give clear written advice on red flags warranting urgent re-assessment even if initial presentation reassuring.

---

16. References

Primary Sources

1. Abu-Arafeh I, et al. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088-1097. PMID: 20722664. DOI: 10.1111/j.1469-8749.2010.03793.x

2. Hershey AD. Pediatric headache: update on recent research. Headache. 2012;52(2):327-332. PMID: 22288386. DOI: 10.1111/j.1526-4610.2011.02088.x

3. Abu-Arafeh I, et al. The childhood migraine syndrome. Nat Rev Neurol. 2021;17(7):449-458. PMID: 34040231. DOI: 10.1038/s41582-021-00497-6

4. Hadidchi S, et al. Headache and Brain Tumor. Neuroimaging Clin N Am. 2019;29(2):291-300. PMID: 30926118. DOI: 10.1016/j.nic.2019.01.008

5. Youssef PE, et al. Episodic and chronic migraine in children. Dev Med Child Neurol. 2020;62(1):34-41. PMID: 31463934. DOI: 10.1111/dmcn.14338

6. Paemeleire K, et al. Migraine without aura. Handb Clin Neurol. 2023;199:103-118. PMID: 38043959. DOI: 10.1016/B978-0-12-823356-6.00007-X

7. Wilne S, et al. The presenting features of brain tumours: a review of 200 cases. Arch Dis Child. 2006;91(6):502-506. PMID: 16547083. DOI: 10.1136/adc.2005.090266

8. Onan D, et al. Debate: differences and similarities between tension-type headache and migraine. J Headache Pain. 2023;24(1):92. PMID: 37474899. DOI: 10.1186/s10194-023-01614-0

9. Winner P, et al. Characteristics of migraine in adolescents: results from Adolescent Migraine Stereotypes (AMSTEL) study. Headache. 2005;45(2):87-96. PMID: 15705113.

10. Monteith TS, et al. Tension type headache in adolescence and childhood: where are we now? Curr Pain Headache Rep. 2010;14(6):424-430. PMID: 20927610. DOI: 10.1007/s11916-010-0149-z

11. Mastria G, et al. Alice in Wonderland Syndrome: A Clinical and Pathophysiological Review. Biomed Res Int. 2016;2016:8243145. PMID: 27868064. DOI: 10.1155/2016/8243145

12. Lahat E, et al. Alice in Wonderland syndrome and infectious mononucleosis in children. J Child Neurol. 1999;14(11):732-735. PMID: 10553727.

13. Wilne SH, et al. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. 2007;8(8):685-695. PMID: 17644483. DOI: 10.1016/S1470-2045(07)70207-3

14. Gaist D, et al. Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. Brain. 2016;139(7):2015-2023. PMID: 27190010. DOI: 10.1093/brain/aww099

15. Wöber-Bingöl Ç. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341. PMID: 23700075. DOI: 10.1007/s11916-013-0341-z

16. Stewart WF, et al. Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol. 1991;134(10):1111-1120. PMID: 1746521.

17. Laurell K, et al. Prognosis of the syndrome of transient headache and neurological deficits with cerebrospinal fluid lymphocytosis. Neurology. 2008;71(24):1973-1980. PMID: 19064881.

18. Anttila P, et al. Tension-type headache in childhood and adolescence. Lancet Neurol. 2006;5(3):268-274. PMID: 16488382. DOI: 10.1016/S1474-4422(06)70376-1

19. Baglioni V, et al. Tension-Type Headache in Children and Adolescents. Life (Basel). 2023;13(3):825. PMID: 36983980. DOI: 10.3390/life13030825

20. Russell MB, et al. Familial occurrence of migraine without aura and migraine with aura. Neurology. 1993;43(7):1369-1373. PMID: 8327138.

21. Eidlitz-Markus T, et al. Obesity and Migraine in Childhood. Curr Pain Headache Rep. 2018;22(6):42. PMID: 29725875. DOI: 10.1007/s11916-018-0696-2

22. Arruda MA, et al. Migraine, tension-type headache, and attention-deficit/hyperactivity disorder in childhood: a population-based study. Postgrad Med. 2010;122(5):18-26. PMID: 20861584. DOI: 10.3810/pgm.2010.09.2197

23. Kernick D, et al. Impact of headache on young people in a school population. Br J Gen Pract. 2008;58(546):678-681. PMID: 18801280. DOI: 10.3399/bjgp08X342660

24. Burstein R, et al. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619-6629. PMID: 25926442. DOI: 10.1523/JNEUROSCI.0373-15.2015

25. Goadsby PJ, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622. PMID: 28179394. DOI: 10.1152/physrev.00034.2015

26. Fumal A, et al. Tension-type headache: current research and clinical management. Lancet Neurol. 2008;7(1):70-83. PMID: 18093564. DOI: 10.1016/S1474-4422(07)70325-3

27. Parisi P, et al. Tension-type headache in paediatric age. Acta Paediatr. 2011;100(4):491-495. PMID: 21143645. DOI: 10.1111/j.1651-2227.2010.02115.x

28. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. PMID: 29368949. DOI: 10.1177/0333102417738202

29. Gelfand AA, et al. Medication overuse headache in children and adolescents. Curr Pain Headache Rep. 2014;18(7):428. PMID: 24849927. DOI: 10.1007/s11916-014-0428-1

30. Lewis DW, et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2002;59(4):490-498. PMID: 12196640.

31. HeadSmart: Be Brain Tumour Aware. Children's Brain Tumour Research Centre, University of Nottingham. www.headsmart.org.uk (accessed 2025)

32. Esposito M, et al. Pediatric migraine and episodic syndromes that may be associated with migraine. Ital J Pediatr. 2013;39:92. PMID: 24423406. DOI: 10.1186/1824-7288-39-92

33. Oskoui M, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93(11):500-509. PMID: 31413170. DOI: 10.1212/WNL.0000000000008105

34. Rastogi RG, et al. Advances in the Acute and Preventive Treatment of Pediatric Migraine. Curr Pain Headache Rep. 2023;27(9):465-475. PMID: 37561313. DOI: 10.1007/s11916-023-01157-8

35. Damen L, et al. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics. 2005;116(2):e295-302. PMID: 16061583. DOI: 10.1542/peds.2004-2742

36. Hamalainen ML, et al. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48(1):103-107. PMID: 9008503.

37. Winner P, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106(5):989-997. PMID: 11061765.

38. Powers SW, et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. N Engl J Med. 2017;376(2):115-124. PMID: 28079671. DOI: 10.1056/NEJMoa1610384

39. Irby MB, et al. Aerobic exercise for reducing migraine burden in adolescents. Headache. 2016;56(3):517-526. PMID: 26868034. DOI: 10.1111/head.12738

40. Bruijn J, et al. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. 2010;30(12):1426-1434. PMID: 20974591. DOI: 10.1177/0333102410365106

41. Slater SK, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31(8):897-905. PMID: 21586650. DOI: 10.1177/0333102411406755

42. Gelfand AA, et al. Medication overuse headache in children and adolescents. Curr Pain Headache Rep. 2014;18(7):428. PMID: 24849927. DOI: 10.1007/s11916-014-0428-1

43. Bachur RG, et al. Intravenous prochlorperazine vs intravenous metoclopramide for the treatment of acute migraine in children. Ann Emerg Med. 2013;62(3):262-268. PMID: 23523847. DOI: 10.1016/j.annemergmed.2013.01.029

44. Pavone P, et al. Migraine in children: a review on its relationship with epilepsy and other neurological disorders. J Pediatr Neurosci. 2012;7(2):79-84. PMID: 23248677. DOI: 10.4103/1817-1745.102563

45. Bille BS. Migraine in school children. Acta Paediatr Scand Suppl. 1962;136:1-151. PMID: 13871378.

46. Powers SW, et al. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics. 2003;112(1):e1-e5. PMID: 12837897.

47. National Institute for Health and Care Excellence. Headaches in over 12 s: diagnosis and management. Clinical guideline [CG150]. London: NICE; 2012.

48. Oskoui M, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93(11):500-509. PMID: 31413170. DOI: 10.1212/WNL.0000000000008105

49. Powers SW, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622-2630. PMID: 24368463. DOI: 10.1001/jama.2013.282533

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to current local and national guidelines. This topic was last updated 2026-01-06.